Literature DB >> 18637115

Serum levels of tumour necrosis factor-alpha and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate--preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy.

M Grim-Stieger1, M Keilani, R M Mader, C Marosi, M Schmidinger, C C Zielinski, V Fialka-Moser, R Crevenna.   

Abstract

The serum cytokine levels (in particular interleukine-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha)) of 61 advanced stage cancer patients receiving palliative chemotherapy as outpatients were determined with quantikine immunoassays. The values were correlated with body mass index (BMI), weight loss and appetite. Furthermore cytokine levels of patients who have died within one year were compared with those of patients who have survived more than a year. Serum levels of IL-6 (median: 1.93 pg/ml, range: 0.32-42.87) and of TNF-alpha (median: 2.55 pg/ml, range: 1.03-34.06) did not correlate with BMI, weight loss and appetite. Serum IL-6 levels of patients with survival time less than one year were significantly higher than the levels of patients who survived more than one year, no significant differences in TNF-alpha serum levels were evident. The data of this observation are consistent with current literature. Due to changes in serum levels of proinflammatory cytokines in response to chemotherapy and additional therapy, it is unlikely that IL-6 and TNF-alpha can be used as independent indicators for weight loss and appetite. Nevertheless, high serum levels of IL-6 correlate with short-time mortality.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637115     DOI: 10.1111/j.1365-2354.2007.00874.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  8 in total

1.  Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer.

Authors:  Sang-Yeon Suh; Youn Seon Choi; Chang Hwan Yeom; Sang Mi Kwak; Ho Min Yoon; Dae Gyun Kim; Su-Jin Koh; Jeanno Park; Myung Ah Lee; Yong Joo Lee; Ah-Ram Seo; Hong-Yup Ahn; Eunji Yim
Journal:  Support Care Cancer       Date:  2013-07-05       Impact factor: 3.603

2.  The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer.

Authors:  Aminah Jatoi; Yingwei Qi; Glenda Kendall; Ruoxiang Jiang; Sheila McNallan; Julie Cunningham; Sumithra Mandrekar; Ping Yang
Journal:  Support Care Cancer       Date:  2009-12-15       Impact factor: 3.603

Review 3.  GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer.

Authors:  Darakhshan Sohail Ahmed; Stéphane Isnard; John Lin; Bertrand Routy; Jean-Pierre Routy
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

Review 4.  A systematic review examining the relationship between cytokines and cachexia in incurable cancer.

Authors:  D Robert Paval; Rebekah Patton; James McDonald; Richard J E Skipworth; Iain J Gallagher; Barry J Laird
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-01-25       Impact factor: 12.910

Review 5.  Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis.

Authors:  Bodo E Lippitz; Robert A Harris
Journal:  Oncoimmunology       Date:  2016-05-11       Impact factor: 8.110

6.  Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes.

Authors:  Gustavo Schvartsman; Angelica M Gutierrez-Barrera; Juhee Song; Naoto T Ueno; Susan K Peterson; Banu Arun
Journal:  Cancer Med       Date:  2017-10-10       Impact factor: 4.452

7.  Plasma concentration of interleukin-6 was upregulated in cancer cachexia patients and was positively correlated with plasma free fatty acid in female patients.

Authors:  Jun Han; Chaocheng Lu; Qingyang Meng; Alice Halim; Thong Jia Yean; Guohao Wu
Journal:  Nutr Metab (Lond)       Date:  2019-11-15       Impact factor: 4.169

8.  Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.

Authors:  Naoto Okada; Rie Matsuoka; Takumi Sakurada; Mitsuhiro Goda; Masayuki Chuma; Kenta Yagi; Yoshito Zamami; Yasuhiko Nishioka; Keisuke Ishizawa
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.